Ten Leading BioPharma Companies Announce Formation of Accumulus Synergy to Develop Global Data Sharing Platform


Funded by Amgen, Astellas, Bristol Myers Squibb, GSK, Janssen, Lilly, Pfizer, Roche, Sanofi and Takeda

The companies will support the rollout of a cloud-based platform with the potential to transform the way the biopharma industry communicates and exchanges information with health authorities worldwide.

BURLINGAME, Calif., Jan. 22, 2021 (GLOBE NEWSWIRE) -- Ten of the world’s leading biopharmaceutical companies today announced the formation of a new non-profit corporation, Accumulus Synergy, Inc., which is intended to support interactions between industry and health authorities worldwide to enable real-time collaboration and data exchange, as well as data submission. 

Accumulus Synergy was formed on July 13, 2020, to develop a cloud-based platform to facilitate data and information sharing with the potential to transform the way the biopharmaceutical industry interacts with health authorities.  The common-platform approach to data sharing aims to make the regulatory process more efficient by leveraging advanced technology and tools for data exchange to benefit patients, help reduce the cost of innovation and ultimately bring patients new safe and effective medicines faster.

“Current methods for data exchange and communication between pharmaceutical companies and global health authorities have not kept pace with advancements in information technology,” said Francisco Nogueira, interim Chief Executive Officer of Accumulus Synergy and Vice President of Regulatory Affairs at Roche.  “In consultation with health authorities, Accumulus Synergy seeks to modernize, integrate, and streamline communication and data exchange between biopharmaceutical companies and global regulators, as well as to facilitate potential regulatory harmonization in priority areas, using the latest in cloud technology.  By creating a powerful data-sharing ecosystem, we have the potential to advance delivery of healthcare. Accumulus Synergy looks to create significant value for patients, healthcare providers, health authorities, and biopharma companies globally.”

The initial members of Accumulus Synergy include Amgen, Astellas, Bristol Myers Squibb, GSK, the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen), Lilly, Pfizer, Roche, Sanofi, and Takeda, which have provided funding to support the platform and initial applications.  Accumulus Synergy plans to consult with the Japanese Pharmaceutical and Medical Devices Agency, the European Medicines Agency, the U.K. Medicines and Healthcare products Regulatory Agency, and the U.S. Food and Drug Administration, as well as other health authorities worldwide.

“I am very excited to see Accumulus progress after over a year of careful planning,” said Mikael Dolsten, Chief Scientific Officer and President, Worldwide Research, Development and Medical at Pfizer.  “This project reflects the importance of collaboration among stakeholders to improve pharmaceutical development, with the potential to enable faster and more efficient exchange of information and data with health authorities.” 

“Collaborations focused on science and advanced technologies make us more efficient and ultimately accelerate our ability to improve outcomes for patients – an approach Sanofi has fully embraced,” said John Reed, Executive Vice President, Global Head of Research & Development at Sanofi. “Accumulus’ coordinated efforts to lead data-sharing solutions will reduce the time it takes to make innovative new medicines available to patients, and that’s a goal worthy of support.”

“The Accumulus Synergy vision is transformative.  Accumulus Synergy will proactively engage global health authorities in building a cloud platform to enable efficient filing and review of documents and data. Importantly, Accumulus will build upon and complement the collaborative efficiency solutions developed by TransCelerate BioPharma, Inc. This will result in an acceleration of medicine access across geographies and reduce drug lag,” added Paul Stoffels, Chief Scientific Officer, Johnson & Johnson.

“We are pleased to see Accumulus advance its strategic objective to transform communication and data exchange between biopharma companies and health authorities, an effort complementary to the objectives of TransCelerate Biopharma. We look forward to our continued collaboration with Accumulus in areas of common interest,” said Dalvir Gill, Chief Executive Officer, TransCelerate Biopharma.

“Health authorities, physicians, and biopharmaceutical companies all share a common purpose to bring safe, transformative medicines to patients as quickly as possible,” added Andy Plump, M.D., Ph.D., President of Research & Development at Takeda. “Accumulus Synergy is an opportunity to reimagine regulatory and data-sharing pathways globally and better deliver on that purpose.”

About Accumulus Synergy

Funded by ten leading biopharma companies, the non-profit Accumulus Synergy, Inc. was formed in 2020 to create a cloud-based platform, to transform data sharing between the biopharma industry and global health authorities.  The common-platform approach aims to improve efficiencies in the regulatory process by leveraging advanced technology, including data science and AI, as well as tools for data exchange to improve patient safety, help reduce the cost of innovation, and ultimately bring patients safe and effective medicines faster. It will work with partner companies, key stakeholders, and global health authorities to build and sustain a platform that meets regulatory, cybersecurity, and privacy requirements spanning clinical, safety, chemistry and manufacturing, and regulatory exchanges and submissions. For more information, please visit

Media Contact: 

Paul Laland


About GlobeNewswire

One Liberty Plaza - 165 Broadway
NY 10006 New York

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Synchronoss Announces Appointment of Jeff Miller as Permanent CEO and President8.3.2021 15:21:20 CETPress release

BRIDGEWATER, N.J., March 08, 2021 (GLOBE NEWSWIRE) -- Synchronoss Technologies, Inc. (NASDAQ: SNCR), a global leader and innovator of cloud, messaging and digital solutions, today announced that its Board of Directors has confirmed Jeff Miller as its President and Chief Executive Officer. Miller had been serving as interim President and CEO of Synchronoss since September 2020 and joined Synchronoss in 2018 as Chief Commercial Officer. Prior to coming to Synchronoss, Miller was President of the Technology Group for IDEAL Industries, a firm focused on designing and delivering solutions for smart commercial buildings and spaces. He also served 16 years with Motorola, most recently as Corporate Vice President and General Manager of Operations in North America for Motorola Mobility, LLC, a division of Lenovo. Miller also held various leadership positions in sales management, marketing, and product management at AT&T during an 11-year tenure. “I have had the opportunity to work closely with

AMG Advanced Metallurgical Group N.V. Announces Long-Term Spent Catalyst Recycling Agreement8.3.2021 15:00:00 CETPress release

Amsterdam, 8 March 2021 --- AMG Advanced Metallurgical Group N.V. ("AMG", EURONEXT AMSTERDAM: "AMG") is pleased to announce that AMG Vanadium has signed a new long-term, multi-year agreement to process and recycle spent catalysts from a major oil refinery operator in North America. Located in Cambridge, Ohio, AMG Vanadium specializes in the environmentally beneficial conversion of oil refinery and power plant waste products into specialty metals used by global steel producers in automotive, energy transmission and infrastructure applications. By using materials that would otherwise be discarded as waste, AMG Vanadium facilitates environmental stewardship, energy conservation and resource recovery. About AMG AMG is a global critical materials company at the forefront of CO2 reduction trends. AMG produces highly engineered specialty metals and mineral products and provides related vacuum furnace systems and services to the transportation, infrastructure, energy, and specialty metals & ch

Nexstim Abp offentliggör EU-tillväxtprospekt avseende en företrädesemission på 6,6 miljoner euro8.3.2021 14:15:00 CETPressemelding

Företagsmeddelande, insiderinformation, Helsingfors den 8 mars 2021 kl. 15.15 (EET) Nexstim Abp offentliggör EU-tillväxtprospekt avseende en företrädesemission på 6,6 miljoner euro Nexstim Abp (NXTMH:HEX, NXTMS:STO) (”Nexstim” eller ”bolag”) meddelar med hänvisning till bolagets företagsmeddelande utgiven tidigare i dag, om en företrädesemission av cirka 6,6 miljoner euro att bolaget har upprättat ett EU-tillväxtprospekt som Finansinspektionen godkände den 8 mars 2021. Bolagets styrelse beslutade att offentliggöra EU-tillväxt prospektet den 8 mars 2021 och det ska notifieras till Sverige. EU-tillväxtprospektet på finska läggs omkring den 8 mars 2021 ut på Nexstims webbplats på och tillhandahålls också på bolagets registrerade adress på Elimäkigatan 9 B, 00510 Helsingfors. Dessutom görs EU-tillväxtprospektet på finska tillgängligt på receptionen på Nasdaq Helsinki på Fabiansgatan 14, 00100 Helsingfors. EU-tillväxtprospektet på engelska och en

Nexstim Plc publishes an EU growth prospectus regarding EUR 6.6 million subscription rights issue8.3.2021 14:15:00 CETPress release

Company announcement, inside information, Helsinki, 8 March 2021 at 3.15 PM (EET) Nexstim Plc publishes an EU growth prospectus regarding EUR 6.6 million subscription rights issue Nexstim Plc (NXTMH:HEX, NXTMS:STO) (”Nexstim” or ”Company”) announces with reference to the company announcement published earlier today regarding a subscription rights issue totaling approximately EUR 6.6 million , that the Company has prepared an EU growth prospectus which the Finnish Financial Supervisory Authority (FIN-FSA) has approved on 8 March 2021. The Board of Directors of Nexstim has resolved to publish the EU growth prospectus on 8 March 2021 and it shall be notified to Sweden. Finnish version of the EU growth Prospectus will be available approximately on 8 March 2021 on the Nexstim’s website at and at the registered office of the Company at Elimäenkatu 9 B, 00510 Helsinki. Moreover, the Finnish version of the EU growth prospectus will be availabl

Saniona får återkoppling från FDA gällande den regulatoriska vägen framåt för Tesomet mot hypotalamisk fetma8.3.2021 14:00:00 CETPressemelding

PRESSMEDDELANDE 8 mars 2021 Saniona (OMX: SANION), ett biofarmaceutiskt företag med klinisk utveckling fokuserad på sällsynta sjukdomar, meddelar idag att det amerikanska läkemedelsverket FDA lämnat återkoppling som ytterligare klarlägger det regulatoriska spåret för Tesomet som behandling av hypotalamisk fetma (HO). Baserat på den erhållna återkopplingen går Saniona vidare med planerna att inleda en fas 2b-studie på HO under första halvåret innevarande år. ”I dagsläget finns inga godkända mediciner för hypotalamisk fetma, en sällsynt sjukdom sekundär till skador i hypotalamus. Sjukdomen kännetecknas av svårhanterlig viktuppgång och kompliceras av okontrollerbar hunger”, säger Rudolf Baumgartner, Sanionas Chief Medical Officer och Head of Clinical Development. ”Återkopplingen från FDA är uppmuntrande, och vi ser fram emot att fortsätta den konstruktiva dialogen med myndigheten medan vi förbereder starten av vår kliniska fas 2b-studie med Tesomet.” Som Saniona tidigare meddelat har FDA

Saniona Receives Feedback from U.S. FDA Providing a Regulatory Path Forward for Tesomet in Hypothalamic Obesity8.3.2021 14:00:00 CETPress release

PRESS RELEASE March 8, 2021 Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced it received feedback from the U.S. Food and Drug Administration (FDA) providing further clarity on a regulatory path for Tesomet in the treatment of hypothalamic obesity (HO). Based on this feedback, Saniona is proceeding with plans to initiate a Phase 2b study in HO in the first half of this year. “There is currently no medicine approved for hypothalamic obesity, a rare disease secondary to hypothalamic injury, characterized by intractable weight gain and complicated by uncontrollable hunger,” said Rudolf Baumgartner, M.D., Chief Medical Officer and Head of Clinical Development at Saniona. “We are encouraged by this feedback from the FDA and look forward to continuing a constructive dialogue with them as we prepare to initiate our Phase 2b clinical trial with Tesomet.” Saniona previously announced that the FDA had highlighted the potential for off-lab

Signify share repurchase periodic update8.3.2021 13:00:00 CETPress release

Press Release March 8, 2021 Signify share repurchase periodic update Eindhoven, the Netherlands –Signify (Euronext: LIGHT), the world leader in lighting, today announced that it has repurchased 160,815 shares in the period March 1 to March 5, 2021. The shares were repurchased at an average price of EUR 36,64 per share and an aggregate amount of EUR 5.9 million. These repurchases were made as part of the company’s repurchase program, which was announced on February 25, 2021. Signify will use the shares to cover obligations arising from its long-term incentive performance share plan and other employee share plans. The total number of shares repurchased under this program to date is 216,690 shares for a total consideration of EUR 7.9 million. Details on the share buyback transactions can be found here. --- END --- For further information, please contact: Signify Investor Relations Thelke Gerdes Tel: +31 6 1801 7131 E-mail: Signify Corporate Communications Elco va